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In terms of potential need, the role of 
organ replacement might be an important 
possibility with neoplastic diseases confined 
to the lung or liver and to a lesser extent to 
the kidney or heart. As a preliminary state-
ment it should be conceded that the role of 
transplantation in treating malignancies of 
these various organs is not yet known. How-
ever, there already is some evidence that 
such therapeutic efforts may not be as effec-
tive as might be hoped. 
A SELF-DEFEATING ASPECT 
From a practical standpoint, the greatest 
appeal of organ replacement in cancer sur-
gery would be that the boundaries of per-
missible resection could be considerably ex-
panded. For example, liver tumors which 
could not be completely excised by standard 
techniques of subtotal hepatectomy might be-
come removable if the whole organ could be 
extirpated. The same might apply for rhab-
domyosarcomas of the heart or for renal or 
pulmonary tumors in patients who could not 
spare the functional loss of one kidney or 
lung. Of course, the extension by this means 
of the surgical procedure would not neces-
sarily ensure against metastases. 
Indeed there is the possibility that the 
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growth of residual tumor could actually be 
accelerated as a consequence of the immuno-
suppressive therapy which is necessary for 
prevention of homograft rejection. There has 
been increasing acceptance of the concept 
that the immunologic system provides a sur-
veillance functionll ,28 by which mutant neo-
plastic cells are identified and either elimi-
nated or restricted in their growth potential. 
The individuality of such cells which allows 
their recognition as foreign has been 
thought to be due to tumor specific anti-
gens. 20,22,21'1,27 ,28,30,37,43,44 
Should the surveillance hypothesis be 
valid, it would follow that neoplastic sequel-
lae of one kind or other would constitute a 
threat in immunosuppressed patients after 
clinical transplantation procedures. Several 
observations that have been made in human 
recipients of whole organ homografts have 
tended to confirm this expectation. 
CLINICAL AND EXPERIMENTAL 
OBSERVATIONS ON THE 
ONCOGENIC PROPERTIES 
OF IMMUNOSUPPRESSION 
IMMUNOSUPPRESSION AND THE 
TRANSPLANTIBILITY OF TUMORS 
A few years ago, three different teams 
used renal homografts that had been ob-
tained from patients whose deaths were 
caused by carcinoma of the lungll,51 or of 
TA
BL
E 
1.
 C
lin
ic
al
 F
ea
tu
re
s 
of
 D
e 
No
vo
 M
al
ig
na
nc
ie
s 
in
 R
en
al 
Tr
an
sp
la
nt
 R
ec
ip
ie
nt
s*
 
+:>
-
0
\ 
D
at
e 
T
ra
ns
pl
an
t 
D
at
e 
o
f 
M
al
ig
na
nc
J 
O
rg
an
s 
S
pl
e-
T
hy
-
P
re
dn
i-
"
7.
pe
 o
f 
I::c
 
N
um
be
r 
P
at
ie
nt
 
C
en
te
r 
A
ge
 
Se
x 
T
ra
ns
pl
an
t 
D
on
or
 
D
ia
gn
os
e 
In
vo
lv
ed
 
n
e
c
to
m
y 
m
e
c
to
m
y 
Im
ur
an
 
s
o
n
e
 
A
LG
 
u
m
o
r 
O
ut
co
m
e 
:::
, 
""
 
;::).
 
1 
P.
 H
. 
D
en
ve
r 
42
 
M
 
9/
30
/6
3 
U
nr
el
at
ed
 
3/
1/
66
 
Ea
r 
Ye
s 
N
o 
Ye
s 
Ye
s 
N
o 
Sq
ua
m
ou
s 
Cu
re
d,
 
f~ CS 
ce
ll 
ca
r·
 
su
rg
ic
al
 
\J"
" 
ci
no
m
a 
e
xc
is
io
n 
~ "" 
2 
T.
 C
. 
D
en
ve
r 
14
 
M
 
5/
29
/6
7 
M
ot
he
r 
11
/1
6/
67
 
Br
ai
n 
Ye
s 
N
o 
Ye
s 
Ye
s 
Ye
s 
R
et
ic
ul
um
 
D
ie
d 
f~ 
ce
ll 
12
/4
/6
7 
sa
rc
o
m
a
 
:::,
.. 
.
: :::,
 
3 
S.
 D
. 
D
en
ve
r 
23
 
M
 
6/
15
/6
5 
Fa
th
er
 
12
/6
/6
7 
Th
yr
oi
d 
Ye
s 
Ye
s 
Ye
s 
Ye
s 
N
o 
R
et
ic
ul
um
 
Di
ed
 
;:s
 
<
') 
Lu
ng
 
ce
ll 
12
/6
/6
7 
~
 
""
 
Li
ve
r 
sa
rc
o
m
a
 
S·
 
St
om
ac
h 
(")
 
Pr
os
ta
te
 
:::
, ;:s
 
P
itu
ita
ry
 
<
') ~
 
.
.
.
, 
Sk
in
 
~
 
Ps
oa
s 
m
u
sc
le
 
s:::
 ~ 
4 
E.
 C
. 
D
en
ve
r 
20
 
F 
9/
15
/6
7 
Fa
th
er
 
4/
11
/6
8 
Br
ai
n 
Ye
s 
No
 
Ye
s 
Ye
s 
Ye
s 
Po
ss
ib
le
 
Al
iv
e 
a
n
d 
I~
 
pl
as
m
a-
w
e
ll 
cy
to
m
a 
3/
15
/6
9 
5 
W
.A
. 
M
in
ne
ap
ol
is
t 
27
 
M
 
Se
pt
. 
'6
4 
B
ro
th
er
 
Ju
ne
 '6
5 
Li
ve
r 
Ye
s 
N
o 
Ye
s 
Ye
s 
N
o 
Ly
m
ph
o-
D
ie
d 
\ 
Br
ai
n 
sa
rc
o
m
a
 
11
/6
/6
5 
Bo
ne
 m
a
rr
o
w
 
6 
M
. 
M
. 
Ed
in
bu
rg
h,
 
26
 
F 
1/
17
/6
6 
M
ot
he
r 
2/
1/
68
 
M
ed
ia
st
in
al
 
No
 
No
 
Ye
s 
Ye
s 
Ye
s 
R
et
ic
ul
um
 
D
ie
d 
Sc
ot
la
nd
t 
ly
m
ph
 n
o
de
s 
ce
ll 
2/
16
/6
8 
Pl
eu
ra
 
sa
rc
o
m
a
 
*
T
he
 c
a
s
e
s
 h
av
e 
be
en
 r
e
po
rt
ed
 e
ls
ew
he
re
.'"
' 4
5,
 4
7 
Si
nc
e 
o
u
r 
o
rig
in
al
 r
e
po
rt
s,
 a
bo
ut
 1
5 
m
o
re
 e
x
a
m
pl
es
 o
f 
m
a
lig
na
nt
 n
e
o
pl
as
ia
 h
av
e 
be
en
 r
e
po
rt
ed
 t
o
 u
s
 f
ro
m
 d
iff
er
en
t 
c
e
n
te
rs
. 
Th
es
e 
ha
ve
 n
o
t 
be
en
 i
nc
lu
de
d 
he
re
 b
ec
au
se
 th
e 
de
ta
ils
 a
re
 n
o
t 
fu
lly
 k
no
w
n 
in
 m
a
n
y 
o
f t
he
 c
a
s
e
s
. 
te
. 
R
. 
H
itc
hc
oc
k:
 P
er
so
na
l c
o
m
m
u
n
ic
at
io
n.
 T
he
 c
a
s
e
 h
as
 b
ee
n 
e
x
te
ns
iv
el
y 
re
v
ie
w
ed
 s
in
ce
 it
 w
a
s
 f
ir
st
 r
e
po
rt
ed
 t
o
 u
s
 b
y 
D
r.
 H
itc
hc
oc
k.
 O
n 
re
tr
os
pe
ct
iv
e 
e
v
a
lu
at
io
n,
 m
a
n
y 
o
f t
he
 c
on
su
lt
in
~ 
pa
th
ol
og
is
ts
 b
el
ie
ve
 th
e 
a
c
tu
a
l d
ia
gn
os
is
 to
 b
e 
u
n
di
ff
er
en
tia
te
d 
c
a
rc
in
om
a,
 r
a
th
er
 th
an
 ly
m
ph
os
ar
co
m
a.
 
tM
. 
F.
 A
. W
oo
dr
u 
f: 
P
er
so
na
l c
o
m
m
u
n
ic
at
io
n.
 
The Prospect of Organ Transplantation in Cancer Surgery 47 
FIG. I. Reticulum cell sarcoma in a 23-year-old male who died of this complication 21h 
years after successful renal homotransplantation. A summary of the clinical and pathologic 
features are under Case 3, TabJe I. 
Left-This 5 cm nodule was one of several found in the liver. 
Right-Malignant reticulum cells have massively infiltrated the thyroid, separating the follicles 
widely ( X 80). 
the pyriform sinus.;;;' In each instance, the 
transplanted kidney was not thought to be 
involved by tumor at the time of the organ 
removal. Good homograft function was ob-
tained with the aid of azathioprine and pred-
nisone therapy. Four to 18 months later, neo-
plastic growth of the same histologic type as 
that which had been present in the donor was 
found in the homografts. 
In all three cases, the accidentally trans-
planted tumors had become autonomous by 
the time the diagnosis was made.;I1·;l;l.,>1 Even 
though immunosuppression was discontinued, 
metastases developed in two of the re-
cipients and led to death. The third patient 
recovered after drug therapy was stopped and 
radical but probably incomplete excision 
carried out of the renal homograft and the 
local neoplastic growth in the transplant 
wound!,t It was concluded that the remain-
ing tumor had undergone rejection coincident 
with recovery from partial immune paralysis. 
THE SPONTANEOUS DEVELOPMENT 
OF NEW TUMORS 
Since neoplastiC and non-neoplastic tissues 
arc rejected by a common mechanism and 
are subject to similar rules of histocompatibil-
ity I1l K ln K ~1I~dKPr I Pd I :lTK41I4:! protection of inad-
vertently transferred tumor by antirejection 
therapy in the renal patients was hardly sur-
prising. A much more specific example of 
the oncogenic effect of immunosuppression 
has been the development of new malig-
nancies in a number of renal homograft re-
cipients whose kidneys were obtained from 
healthy donors. This complication was first 
reported from our institutions3ti•45,47 on the 
basis of four of our own cases and two more 
from other centers (Table 1). In at least 
four of the six patients the neoplasia was 
of cells of mesenchymal origin. Approxi-
mately a dozen other published lH .11l or un-
published instances of de novo malig-
nancies after renal transplantation have 
been brought to our attention. About half 
of these were carcinomas and the rest were 
lymphomas. 
The development of an occasional neo-
plasm in any patient group of substantial 
size would not be particularly alarming. How-
ever, the incidence of malignancies in our 
renal recipient pool far exceeds that which 
would be expected by chance. Before May, 
1967, approximately 170 patients were 
treated with renal homografts. In about 70 
percent of the cases, survival of six months 
or longer was obtained. It was within this 
group of less than 120 chronic survivors that 
the four malignancies were detected, giving 
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FIG. 2. Case 2 (Table 1), in the Denver series of patients who developed malignancies 
after renal homotransplantation. Tumor nodules are seen in the left occipilallobe and cere-
bellum . The flattened gyri reflect increased intracranial pressure caused by the tumor. 
Insel-The large, uniform cells with indistinct cytoplasm and round to oval nuclei are 
characteristic of reticulum cell sarcoma ( X 350). 
an incidence of between three and four per-
cent in those patients who lived long enough 
for meaningful observations to be made. 
The diagnosis of malignant neoplasia was 
made postmortem in one of the four patients 
followed by us. In that case, renal homo-
transplantation had been carried out more 
than two and one-half years previously . 
Death occurred six days after emergency 
vagotomy and gastrectomy were performed 
to control massive upper gastrointestinal 
bleeding. The resected portion of the stom-
ach contained several ulcers in the bases of 
which were small foci of reticulum cell sar-
coma that were strikingly similar histologi-
cally to larger deposits found at autopsy in 
many other organs (Fig. 1). 
In the other three patients, the presence 
of neoplasia was appreciated during life. 
In one case, the diagnosis of reticulum cell 
sarcoma was made by craniotomy a few 
days before the very extensive tumor of the 
brain (Fig. 2) caused the patient's death 
almost six and one-half months after renal 
transplantation. A third patient developed 
a mass in the basal diencephalon that was 
biopsied with a stereotaxic instrument and 
which proved to be a plasmocytoma. The 
doses of the immunosuppressive agents were 
drastically reduced and the brain stem was 
treated with local irradiation. Fortunately 
the kidney did not reject (Fig. 3) but the 
tumor apparently underwent involution since 
she has now been well for more than a year. 
The fourth patient developed a squamous 
cell carcinoma of the ear two and one-half 
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WBC 
Cer 
(ml/min.l 
BUN 
(mg per 100 mil 
AZATHIOPRINE 
(mg) 
PREDNISONE 
(mg) 200 
LD 152 
TUMOR 
IRRADIATION 
~
ALG o 10 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 
• RENAL TRANSPLANTATION 
TIME IN DAYS 
FIG. 3. The course of a patient (Case 4) who developed a plasma-cytoma in the dien-
cephalon more than 7 months after renal homotransplantation from her father. The tumor 
was irradiated and the doses of both azathioprine and prednisone were drastically reduced. 
The neurologic deficit was partially reversed and has not progressed in the subsequent year. 
Renal function has remained good. (By permission of Grune and Stratton, New York, 1969) 
years after renal transplantation (Table 1). 
Radical surgical excision resulted in an ap-
parent cure. 
In recipients of renal homografts, there 
could be many ways in which biologic sur-
veillance might be eroded, beginning with 
the loss of immunologic reactivity that may 
accompany the pre-existing uremia.15.52 In 
addition, each of the main immunosuppres-
sive agents, azathioprine,1:!.13 prednisone,1.2 
8.11.;;3 and ALG4.;;.O,7,1O,lU,17.24 has been shown 
in animals either to: (1) increase a normally 
low incidencc of spontaneous, virus-induced, 
or chemically-initiated tumors; (2) to fa-
cilitate the ease with which malignant cells 
can be transplanted; or (3) to accelerate 
metastatic growth. In addition, thymec-
tomy4,lO,23.29.32.35 or splenectomi have a sim-
ilar but less certain effect. 
An additional factor was suggested in our 
reports38.4G ,47 to explain the disproportionate 
number of mesenchymal tumors in the 
patients. 
The possibility was raised that the chronic 
stimulation of the host reticuloendothelial 
system by antigens of the homograft was 
responsible for the nature of the malignan-
cies. The role of antigenic stimulation in in-
creasing the incidence of experimental lym-
phomas has been well established. 14,34,39.49 
THE EFFECT ON METASTASES 
It was mentioned above that azathio-
prine,13 prednisone,1,2,9,53 ALG24 and splen-
ectomy3 all can increase the rapidity of 
metastases of experimental tumors under the 
appropriate circumstances. There is no real 
reason to doubt that the same thing would 
pertain clinically. The very explosive be-
havior of recurrent disease in some of our 
liver transplant recipients was compatible 
with this concept. 
We have had four recipients of orthotopic 
liver homografts who lived through the im-
mediate effects of this operation and who 
then became available for long term obser-
vation.4o,48 In all four, hepatic cell carci-
noma (hepatoma) was the indication for the 
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29 d ys 
74 days 
TABLE 2. The Fate of Four Patients Who Received Liver Replacement for the Indica-
tion of Hepatoma and Who Lived Long Enough after Operation to Permit Observations 
About the Behavior of the Malignancy* 
Metastases Location Metastases Organs Cause and 
Fi rst Detected First Treatment to Ultimately Time of 
Number Days Postop Metastases Metastases Homograft Involved Death 
90 Lungs Vincristin Yes (autopsy) Brain, lungs, Carcinomatosis 
sulphate, liver and 400 days 
surgical other 
excision of a bdominal 
intraabdominal organs 
tumors 
2 Free of tumor Alive 1 year 
3 60 Lungs Yes (open Lungs. liver, Alive 11 
biopsy) skeleton; months 
(?) brain 
4 29 Lungs Yes (liver Lungs, liver; Alive 5 months 
scan) (?) other 
abdominal 
organs 
'The followup s are to M a r ch 15. 1969. 
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FIG. 4. Extremely rapid development of pul-
monary metastases in a 15-year-old boy . The 
indication for orthotopic liver transplantation 
was hepatoma. 
A-The chest is clear 6 days after operation. 
B-Twenty-nine days postoperative. Two 
metastases are visible in the left lower lung field 
(arrows). 
C-Five days later the tumor deposits previ-
ously seen have grown in size (horizontal arrows) 
and a third focus can now be identified in the 
right upper lobe (vertical arrow). 
D-Forty-four days postoperative. Only 10 
days have elapsed since the I'ast examination. 
Metastatic growths are scattered throughout the 
lungs (arrows) . 
E--.Seventy-four days postoperative. 
F-Four months postoperative. Transient 
dyspnea was first noticed several weeks later. 
) 
liver replacement. One of the patients IS 
still alive and free of evident metastases 
after 13 months. Recurrent neoplasm soon 
became manifest in the other three. 
The general features of the cases are sum-
marized in Table 2. In the three patients who 
developed carcinomatosis, the diagnosis of 
recurrent malignancy was first made from 
29 days to 13 weeks postoperatively on the 
basis of new abnormalities in the chest 
x-rays. After the first lesions became visible, 
these and other deposits enlarged with great 
rapidity (Fig. 4). 
The first chronic survivor after orthotopic 
hepatic homotransplantation was a 19-month-
old child. Three months after operation and 
a few days after pulmonary metastases were 
diagnosed, she was found to have a mass 
in thc right upper quadrant between the 
transverse colon and the liver. Because of its 
proximity to the cholecystoduodenostomy, 
the recurrence was excised; it weighcd 28 
grams. Other intra-abdominal masses soon 
appeared. The largest of these was in the left 
lowcr abdomcn and pelvis and eventually 
caused obstruction of the sigmoid colon and 
both ureters (Figs. 5-A and 5-B). More than 
seven months after transplantation , 164 
grams of the bulky pelvic tumor were re-
moved piecemeal along with thc uterus and 
one ovary. Small mctastatic nodules were 
present throughout thc rest of the abdomen. 
Temporary palliation was obtained (Figs. 
5-C and 5-D). Eventually, a huge metastasis 
became evident in the same approximate sub-
hepatic location as the first one that had been 
resected. It appeared to compress the chole-
cystoduodenostomy and it may have been 
partly responsible for the jaundice that de-
velopcd during the last few weeks of life. 
Eventually, the child developed Jacksonian 
seizures, lapsed into coma, and died 400 days 
after the homotransplantation. At autopsy, 
large deposits of tumor were found within 
52 Basic Problems and Advances in Cancer Surgery 
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the calvarium, thorax, and abdominal cavity. 
It was of special interest that the liver homo-
graEt was the site of two moderately large 
neoplastic nodules (Fig. 6). In this case, 
the arterial blood supply of the transplanted 
organ had thrombosed probably a long time 
before death.4'; .. D~ Consequently, the spread 
of the tumor was most likely via the portal 
vein. 
The behavior of the metastases in the 
other 2 patients was similar (Table 2), but 
the rate of tumor growth was even more 
rapid. Both of these recipients are alive 5 
and 11 1/2 months post-transplantation. How-
ever, they are dying of widespread recur-
rences in the lungs and elsewhere. In both 
cases, it is known that the homograft is un-
dergoing malignant invasion. A liver biopsy 
of one of the patients during the tenth post-
operative month contained carcinoma. The 
liver scans of the other shows striking hepa-
10mega'ly as well as mUltiple filling defects. 
rn the field of kidney transplantation an 
observation by Williams et al·;11 may be rele-
van t to the question of metastatic accelera-
tion. They performed renal homotransplanta-
tion in a child 6 months after excision of a 
Wilm's tumor. Sixteen months after trans-
plantation, at a time when a cure of this kind 
of neoplasm would usually have been assured 
under normal condi tions, metastases became 
apparent leadi ng to death within a few 
weeks. 
GENERAL CONCLUSIONS 
The clinical trials of organ transplantation 
as part of the surgical treatment of malig-
nancy have not been large in number. Even 
in some of these patients who developed 
metastases, there is no question but that life 
FtG . 6. The hepat ic honlOgraft removed 
at :lutopsy more than 13 months after 
orthotopic liver transplantation in a 19-
monlh-old liver recipient whose indication 
for operation was hepatoma. The case is 
the same as that shown in Figure 5. Note 
the 2 large metastatic nodules in the supe-
rior portion of the right lobe of the homo-
grafted liver. (By permission of Surg. 
Gynec . Obstet. 128:327, 1969). 
was prolong\:d and at least temporarily made 
more pleasant by the control of the primary 
neoplastic process. If only for this reason, it 
WOll ld seem premature to abandon the hope 
of using transplantation procedures in highly 
selected and otherwise uotreatable victims of 
local cancer. Tn addition, the feasibility of 
achieving a more lasting benefit has already 
been demonstrated in at least one patient, a 
16-year-old girl who has no detectable recur-
FtG. 5 . Palliation in a child who developeJ recurrences a few months after orthotopic 
liver transplantation for hepatoma. A 28 gram Illetastasis in the right upper quadrant was 
excised 99 Jays post-transplantation. Four months later, exploration was again necessary in 
order to relieve obstruction of the sigmoid colon and ureters. 
A-I ntravenous pyelogram obtained 219 days after transplantation. 
S- Bariulll enema performed the same day. The rectum is defl'ected to the right ; the sig-
moid colon is displaced upward and posteriorly. 
C-Shortly after the above examinations, the tumor mass weighing 164 grams was removed 
from the pelvis. An IVP performed 2 weeks later demonstrated relief of the bilateral ureteral 
destruction. 
D--Barium enema examination 241 days post-transplantation. The colon and rectum ap-
pear normal without displacement. 
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renee more than a year after liver replace-
ment for hepatoma. 
If it is elected to attempt transplantation 
in treating malignancies of various organs, it 
will be of great importance in future cases 
to be even more careful than in the past in 
screening prospective candidates. The experi-
ence acquired so far suggests that if the neo-
plasm is not completely removed, a rapidly 
progressive downhill course from carcinoma-
tosis can be expected. If total extirpation is 
not achieved, it is highly likely that the im-
mune suppression can contribute to the rap-
idity of growth of the secondary deposits. 
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